Biopharma VC Exits 2005-2007: Cheap IPOs, Expensive Acquisitions

Over the past three years, acquisitions have outperformed IPOs in terms of step-ups and total value. Here we take a look at the average valuations each year for the two exit categories. The figures suggest that although IPO is the logical exit, in most cases investors will advocate exploring M&A almost all of the time as well.

Although 2007 saw the so-called IPO window open up a bit for biotechs eager to test their mettle on the public markets, over the past three years, public financings have been relatively weak exit opportunities for venture capitalists. (See "Is It Getting Breezy in Here? Biotech IPO Climate Improving," START-UP, September 2007 Also see "Is it Getting Breezy In Here? Biotech IPO Climate Improving" - Scrip, 1 September, 2007..) Acquisitions continue to outperform IPOs in terms of step-ups and total value, and in 2007 it became evident that basically any company wading into a road show with potential public backers was probably playing the M&A side of the fence as well. (See "Reviewing 2007 to Forecast 2008," IN VIVO, January 2008 [A#200880003].) In 2007 we saw Adnexus Therapeutics Inc. (a division of Bristol-Myers Squibb Co.), NovaCardia Inc. (a division of Merck & Co. Inc.), and Reliant Pharmaceuticals Inc. (a division of GlaxoSmith Kline PLC) each file to go public and each, seemingly at the last moment, pull their IPOs in favor of an acquisition offer. [See Deal][See Deal][See Deal]

It isn’t hard to see why. Not only did M&A out-value IPO on an average basis (see Exhibit 1), but...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Ordspono Will Be Regeneron’s First Independent European Launch

 

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.

Galderma Gets First Biologic To Market With Nemluvio Approval

 

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By 

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.